| Aleksandra Simic Sander, MD | |
|
3011 E Barnett Rd, Medford, OR 97504 | |
| (541) 789-4673 | |
| (541) 789-2121 |
| Full Name | Aleksandra Simic Sander |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 32 Years |
| Location | 3011 E Barnett Rd, Medford, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487618328 | NPI | - | NPPES |
| 286432 | Medicaid | OR | |
| CV0082 | Other | OR | RR MEDICARE GROUP NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD24152 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Asante Rogue Regional Medical Center Hospice Serv | Medford, OR | Hospice |
| Asante Rogue Regional Medical Center | Medford, OR | Hospital |
| Asante Three Rivers Medical Center | Grants pass, OR | Hospital |
| Asante Ashland Community Hospital | Ashland, OR | Hospital |
| Fairchild Medical Center | Yreka, CA | Hospital |
| Providence Medford Medical Center | Medford, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Asante | 0547177321 | 88 |
| Asante Three Rivers Medical Center Llc | 9931197993 | 80 |
News Archive
The Johns Hopkins Bloomberg School of Public Health today announced that Bloomberg Philanthropies, founded by businessman, philanthropist, World Health Organization Global Ambassador for Noncommunicable Diseases, and three-term mayor of New York City Michael R. Bloomberg, will give $300 million to create the Bloomberg American Health Initiative.
A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery.
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors originally licensed to Cornerstone from the Feinstein Institute for Medical Research.
Significant new research from Warwick Business School and Queen Mary, University of London, warns that delays and variability in the approvals process for clinical research could be causing pharmaceutical companies to look outside the UK and risks the country losing some of its most experienced researchers.
A new study, presented today at the Society of NeuroInterventional Surgery's 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.
› Verified 9 days ago
| Entity Name | Asante |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770587107 PECOS PAC ID: 0547177321 Enrollment ID: O20031219000238 |
News Archive
The Johns Hopkins Bloomberg School of Public Health today announced that Bloomberg Philanthropies, founded by businessman, philanthropist, World Health Organization Global Ambassador for Noncommunicable Diseases, and three-term mayor of New York City Michael R. Bloomberg, will give $300 million to create the Bloomberg American Health Initiative.
A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery.
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors originally licensed to Cornerstone from the Feinstein Institute for Medical Research.
Significant new research from Warwick Business School and Queen Mary, University of London, warns that delays and variability in the approvals process for clinical research could be causing pharmaceutical companies to look outside the UK and risks the country losing some of its most experienced researchers.
A new study, presented today at the Society of NeuroInterventional Surgery's 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.
› Verified 9 days ago
| Entity Name | Hematology Oncology Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043263619 PECOS PAC ID: 1951393156 Enrollment ID: O20040330001310 |
News Archive
The Johns Hopkins Bloomberg School of Public Health today announced that Bloomberg Philanthropies, founded by businessman, philanthropist, World Health Organization Global Ambassador for Noncommunicable Diseases, and three-term mayor of New York City Michael R. Bloomberg, will give $300 million to create the Bloomberg American Health Initiative.
A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery.
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors originally licensed to Cornerstone from the Feinstein Institute for Medical Research.
Significant new research from Warwick Business School and Queen Mary, University of London, warns that delays and variability in the approvals process for clinical research could be causing pharmaceutical companies to look outside the UK and risks the country losing some of its most experienced researchers.
A new study, presented today at the Society of NeuroInterventional Surgery's 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.
› Verified 9 days ago
| Entity Name | Asante Three Rivers Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801891809 PECOS PAC ID: 9931197993 Enrollment ID: O20040506000367 |
News Archive
The Johns Hopkins Bloomberg School of Public Health today announced that Bloomberg Philanthropies, founded by businessman, philanthropist, World Health Organization Global Ambassador for Noncommunicable Diseases, and three-term mayor of New York City Michael R. Bloomberg, will give $300 million to create the Bloomberg American Health Initiative.
A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery.
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors originally licensed to Cornerstone from the Feinstein Institute for Medical Research.
Significant new research from Warwick Business School and Queen Mary, University of London, warns that delays and variability in the approvals process for clinical research could be causing pharmaceutical companies to look outside the UK and risks the country losing some of its most experienced researchers.
A new study, presented today at the Society of NeuroInterventional Surgery's 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aleksandra Simic Sander, MD Po Box 4749, Medford, OR 97501-0227 Ph: (541) 789-4111 | Aleksandra Simic Sander, MD 3011 E Barnett Rd, Medford, OR 97504 Ph: (541) 789-4673 |
News Archive
The Johns Hopkins Bloomberg School of Public Health today announced that Bloomberg Philanthropies, founded by businessman, philanthropist, World Health Organization Global Ambassador for Noncommunicable Diseases, and three-term mayor of New York City Michael R. Bloomberg, will give $300 million to create the Bloomberg American Health Initiative.
A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery.
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors originally licensed to Cornerstone from the Feinstein Institute for Medical Research.
Significant new research from Warwick Business School and Queen Mary, University of London, warns that delays and variability in the approvals process for clinical research could be causing pharmaceutical companies to look outside the UK and risks the country losing some of its most experienced researchers.
A new study, presented today at the Society of NeuroInterventional Surgery's 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.
› Verified 9 days ago
Helen Koenigsman, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1333 E Barnett Rd, Medford, OR 97504 Phone: 541-779-4711 | |
Dr. Todd S Kotler, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 520 Medical Center Drive, Ste 200, Medford, OR 97504 Phone: 541-282-6606 Fax: 541-282-6601 | |
Dr. Mark G Moran, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 520 Medical Center Drive, Ste 200, Medford, OR 97504 Phone: 541-282-6606 Fax: 541-282-6601 | |
Dr. June Symens, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 555 Black Oak Dr Ste 400, Medford, OR 97504 Phone: 541-821-6090 | |
Donald L Bowser, NP Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 520 Medical Center Dr, Suite 100, Medford, OR 97504 Phone: 541-789-5704 Fax: 541-789-5989 | |
Samridhi Amba, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 827 Spring St, Medford, OR 97504 Phone: 541-732-7600 | |
Margaret Sara Fairhurst, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1698 E Mcandrews Rd Ste 400, Medford, OR 97504 Phone: 541-732-7960 |